Gottfried von Keudell1, Alison J Moskowitz2. 1. Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY, USA. 2. Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY, USA. moskowia@mskcc.org.
Abstract
PURPOSE OF REVIEW: The outcome of patients with lymphoid malignancies has markedly improved in recent years which is likely due to a combination of advances in supportive care, and therapeutic options. In this article, we will provide an overview over the role PI3-kinase signalling, one of the most important dysregulated pathways in cancer, and its successful inhibition in lymphoma. RECENT FINDINGS: PI3-kinase inhibitors have shown remarkable activity in an increasing subset of patients with non-Hodgkin lymphomas. The first drug to be approved was idelalisib for patients with relapsed/refractory follicular lymphoma and CLL/SLL as monotherapy, or in combination with rituximab, respectively. After an initial setback related to increased toxicity including deaths observed in several upfront studies, there has been a resurgence in interest in this pathway following the promising efficacy of second-generation PI3K inhibitors including in patients with T cell lymphomas. PI3K inhibition continues to be an invaluable tool in the therapy of patients with lymphoid malignancies if managed cautiously. Preclinical models are helpful in predicting possible side effects and identifying new lymphoma subtypes that may be susceptible to this class of agents. The future will likely involve rationally designed combinatorial approaches to deepen the response rate and prevent the emergence of resistance.
PURPOSE OF REVIEW: The outcome of patients with lymphoid malignancies has markedly improved in recent years which is likely due to a combination of advances in supportive care, and therapeutic options. In this article, we will provide an overview over the role PI3-kinase signalling, one of the most important dysregulated pathways in cancer, and its successful inhibition in lymphoma. RECENT FINDINGS: PI3-kinase inhibitors have shown remarkable activity in an increasing subset of patients with non-Hodgkin lymphomas. The first drug to be approved was idelalisib for patients with relapsed/refractory follicular lymphoma and CLL/SLL as monotherapy, or in combination with rituximab, respectively. After an initial setback related to increased toxicity including deaths observed in several upfront studies, there has been a resurgence in interest in this pathway following the promising efficacy of second-generation PI3K inhibitors including in patients with T cell lymphomas. PI3K inhibition continues to be an invaluable tool in the therapy of patients with lymphoid malignancies if managed cautiously. Preclinical models are helpful in predicting possible side effects and identifying new lymphoma subtypes that may be susceptible to this class of agents. The future will likely involve rationally designed combinatorial approaches to deepen the response rate and prevent the emergence of resistance.
Entities:
Keywords:
B cell receptor; CLL; Follicular lymphoma; Lymphoma; PI3-kinase; T cell lymphoma; Tumor microenvironment
Authors: Ningshu Liu; Bruce R Rowley; Cathy O Bull; Claudia Schneider; Andrea Haegebarth; Christoph A Schatz; Paul R Fracasso; Dean P Wilkie; Martin Hentemann; Scott M Wilhelm; William J Scott; Dominik Mumberg; Karl Ziegelbauer Journal: Mol Cancer Ther Date: 2013-10-29 Impact factor: 6.261
Authors: Megan M Kaneda; Karen S Messer; Natacha Ralainirina; Hongying Li; Christopher J Leem; Sara Gorjestani; Gyunghwi Woo; Abraham V Nguyen; Camila C Figueiredo; Philippe Foubert; Michael C Schmid; Melissa Pink; David G Winkler; Matthew Rausch; Vito J Palombella; Jeffery Kutok; Karen McGovern; Kelly A Frazer; Xuefeng Wu; Michael Karin; Roman Sasik; Ezra E W Cohen; Judith A Varner Journal: Nature Date: 2016-12-14 Impact factor: 49.962
Authors: Steven M Horwitz; Raphael Koch; Pierluigi Porcu; Yasuhiro Oki; Alison Moskowitz; Megan Perez; Patricia Myskowski; Adam Officer; Jacob D Jaffe; Sara N Morrow; Kerstin Allen; Mark Douglas; Howard Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Jon C Aster; David Weaver; Francine M Foss; David M Weinstock Journal: Blood Date: 2017-12-12 Impact factor: 22.113
Authors: Julia Hoellenriegel; Sarah A Meadows; Mariela Sivina; William G Wierda; Hagop Kantarjian; Michael J Keating; Neill Giese; Susan O'Brien; Albert Yu; Langdon L Miller; Brian J Lannutti; Jan A Burger Journal: Blood Date: 2011-07-29 Impact factor: 22.113
Authors: Paul M Barr; Gene B Saylors; Stephen E Spurgeon; Bruce D Cheson; Daniel R Greenwald; Susan M O'Brien; Andre K D Liem; Rosemary E Mclntyre; Adarsh Joshi; Esteban Abella-Dominicis; Michael J Hawkins; Anita Reddy; Julie Di Paolo; Hank Lee; Joyce He; Jing Hu; Lyndah K Dreiling; Jonathan W Friedberg Journal: Blood Date: 2016-03-11 Impact factor: 22.113
Authors: Lakshmi Srinivasan; Yoshiteru Sasaki; Dinis Pedro Calado; Baochun Zhang; Ji Hye Paik; Ronald A DePinho; Jeffrey L Kutok; John F Kearney; Kevin L Otipoby; Klaus Rajewsky Journal: Cell Date: 2009-10-30 Impact factor: 41.582
Authors: Steven E Coutré; Jacqueline C Barrientos; Jennifer R Brown; Sven de Vos; Richard R Furman; Michael J Keating; Daniel Li; Susan M O'Brien; John M Pagel; Martin H Poleski; Jeff P Sharman; Nai-Shun Yao; Andrew D Zelenetz Journal: Leuk Lymphoma Date: 2015-05-19
Authors: Marco Kirchenwitz; Stephanie Stahnke; Silvia Prettin; Malgorzata Borowiak; Laura Menke; Christian Sieben; Carmen Birchmeier; Klemens Rottner; Theresia E B Stradal; Anika Steffen Journal: Cells Date: 2022-05-16 Impact factor: 7.666
Authors: Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388